PsARC response assessment on TNF inhibitor treatment
at 12 weeks
tests per year, UK, at 12 weeks of treatment
“Etanercept, adalimumab or infliximab treatment should be discontinued in people whose psoriatic arthritis has not shown an adequate response using the Psoriatic Arthritis Response Criteria (PsARC) at 12 weeks.”
NICE TA199, Etanercept, infliximab and adalimumab for the treatment of psoriatic arthritis, 2010-08
- Kind of source
- Clinical guideline
- Read on
- 2026-11-06
- Daily check
- Quote found at the source on 2026-11-06
- What to know
- PsARC combines tender and swollen joint scores with patient and physician global assessments; the result is recorded at the specialist review.
Used in
Kept as evidence; no figure on the platform is computed from it yet.